Key facts
- It has raised $80.0M; the latest was Early Stage VC in Nov 2024.
- Notable investors include Alexandria Venture Investments, ARCH Venture Partners, Sofinnova Partners, Pfizer Ventures, UPMC Enterprises — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Mozart Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Mozart Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mozart Therapeutics
Developer of disease-modifying therapies designed to focus on developing novel immune engagers. The company offers CD8 T-cell immune modulators for the treatment of autoimmune diseases, as it specifically targets a subset of T-lymphocytes to delay the onset and ameliorate targeted autoimmune diseases, enabling doctors to administer state-of-the-art drugs for treating autoimmune disorders in patients.
- Sector
- Healthcare
- HQ
- Seattle, WA, United States
- Founded
- 2020
- Employees
- 43
- Website
- mozart-tx.com/
- Ownership
- Privately Held (backing)
Mozart Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mozart Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mozart Therapeutics in its N-PORT filings yet. We sweep new filings monthly.